GPC3 CAR-T cell compositions and methods of making and using the same
AssigneeEutilex Co., Ltd.
InventorsByoung S. Kwon, Kwanghee Kim, Jiwon Chung, Young Gyoon Chang, Bo-Rim Yi, Jungyun Lee, Seunghyun Lee, Sun-Woo Im, Jinkyung Choi, Hyuntae Son, Hye Mi Lee
Life of this patent
Estimating the term…
Abstract
Provided are CAR-T compositions that are directed to GPC3, including chimeric receptors, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.
Claims22
An immune cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen-binding domain that binds specifically to glypican-3 (GPC3), a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises a light chain variable domain represented by SEQ ID NO:
- 10 and a heavy chain variable domain represented by SEQ ID NO:
- 8.
A nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises:
- an extracellular antigen-binding domain that binds specifically to glypican-3 (GPC3), a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises a light chain variable domain represented by SEQ ID NO:
- 10 and a heavy chain variable domain represented by SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.